VSTM - Verastem, Inc.
| Previous Close | 8.83 |
| Open | 8.79 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 8.65 - 8.94 |
| 52 Week Range | 2.77 - 10.35 |
| Volume | 1,741,445 |
| Avg. Volume | 2,359,593 |
| Market Cap | 643.933M |
| Beta | 3.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.68 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- Zacks•3 days ago
Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Market Realist•9 days agoAnalysts Are Bullish on Verastem in September
On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.
- ACCESSWIRE•14 days ago
This Cancer Stock is up Over 3900%
HENDERSON, NV / ACCESSWIRE / September 7, 2018 / A fascinating biotech firm we discovered PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the last ten trading session going from a low of $0.0039 ...
- Business Wire•15 days ago
Verastem Oncology Announces Investigator Sponsored Study on Duvelisib in Combination with Venetoclax
Verastem, Inc. (VSTM), operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Business Wire•16 days ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to eleven new employees to purchase an aggregate of 202,230 shares of Verastem Oncology's common stock. The options were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $9.87 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on September 4, 2018.
SmarterAnalyst•21 days agoHealthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
Hedge fund manager Mitchell J. Blutt of the $1.5 billion Consonance Capital fund has made some intriguing portfolio shifts in the last quarter, including boosting his position in biopharma firm Catalyst Pharmaceuticals (NASDAQ:CPRX) and initiating stakes in drug makers Verastem (NASDAQ:VSTM) and Sesen Bio (NYSE:SESN). Blutt is seizing the opportunity with Catalyst, dialing up his hedge fund firm’s stake in the company to the tune of a 22% boost up.
- Benzinga•22 days ago
The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) Abbott Laboratories (NYSE: ...
- Business Wire•22 days ago
Verastem Oncology Appoints Robert E. Gagnon as Chief Financial Officer
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Robert E. Gagnon, an experienced financial executive, as Chief Financial Officer, effective August 28, 2018. A stock option to purchase 350,000 shares of Verastem Oncology’s common stock will vest as to 25% of the shares on the first anniversary of the date of hire and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the date of hire, provided that Mr. Gagnon continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
- Zacks•last month
Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
- Motley Fool•last month
Here's Why Verastem Jumped Higher Today
Hint: It has nothing to do with yesterday's earnings release.
- ACCESSWIRE•last month
Pot Stocks & Biotech Stocks to Watch in 2018 & Beyond
CORAL GABLES, FL / ACCESSWIRE / August 9, 2018 / Healthcare and biotechnology indexes are in the green this morning along with major markets pushing higher. The iShares Biotechnology Index (IBB) has risen an impressive 8.9% this year and has begun turning toward its 52-week high. GT Biopharma (GTBP) is a small cap biotech company with a vast pipeline of treatments.
- Associated Press•last month
Verastem: 2Q Earnings Snapshot
On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 30 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
- Business Wire•last month
Verastem Oncology Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to fifty-seven new employees to purchase an aggregate of 1,031,500 shares of Verastem Oncology’s common stock. The options were granted as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $7.74 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on August 1, 2018.
- Business Wire•last month
Verastem Oncology Reports Second Quarter 2018 Financial Results
Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today reported financial results for the quarter ended June 30, 2018 and provided an overview of certain corporate developments.
- ACCESSWIRE•2 months ago
Undiscovered Biotech Firm that Could Make Investors Early Very Happy
HENDERSON, NV / ACCESSWIRE / July 30, 2018 / Biotech companies that are advancing their research are the type of company that, smart investors are actively looking for. One small cap biotech company that we have discovered BRTX (BioRestorative Therapies, Inc.). As BRTX prepares for it's Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar of most investors, which presents a great opportunity to investors that are currently in the know on BRTX.
- ACCESSWIRE•2 months ago
Upcoming Catalysts Could Send This Unknown Stock Up 300% or More
Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.
- ACCESSWIRE•3 months ago
Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks
Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...
- Business Wire•3 months ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to nine new employees to purchase an aggregate of 201,500 shares of Verastem Oncology’s common stock. The options were granted as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $6.95 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 2, 2018.
- Business Wire•3 months ago
Verastem Oncology to Participate in the Oppenheimer Boston Oncology Insight Summit
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will participate in the Oppenheimer Boston Oncology Insight Summit on July 10-11, 2018, in Boston, Massachusetts. Members of Verastem Oncology’s executive team will participate in the event. Verastem, Inc. (VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients.
- Business Wire•3 months ago
Verastem Oncology to Join Russell 3000® Index
Verastem, Inc. (VSTM), the Company or Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective upon the US market open on Monday, June 25, 2018. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
- ACCESSWIRE•3 months ago
Biotech's Making Great Progress
HENDERSON, NV / ACCESSWIRE / June 22, 2018 / This is set to be the fifth consecutive quarter in which at least ten biotech companies have made it to market on an U.S. exchanges and have raised at least ...
- ACCESSWIRE•3 months ago
Verastem Upcoming FDA Review, Big Steps Forward in the Oncology Space
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Verastem, Inc. (VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. The company recently announced the acceptance of its duvelisib New Drug Application by the U.S. Food and Drug Administration, with a Priority Review date later this year. The company recently made one oral and three poster presentations at the 23rd Congress of the European Hematology Association.
Market Realist•3 months agoAnalysts’ Recommendations for Verastem
This month, Verastem (VSTM) and Yakult Honsha entered into an agreement where Yakult Honsha received the rights to develop and commercialize Verastem’s duvelisib for the treatment, prevention, and diagnosis of all oncology indications in Japan.
- Market Realist•3 months ago
Why Verastem Stock Rose 31% on June 18
On June 18, Verastem (VSTM) stock rose ~31.4% from $6.53 on June 15 to close at $8.58, which represents ~319% growth from its 52-week low of $2.05 on June 19, 2017. The stock also hit its 52-week high of $8.75 on June 18. On June 15, Verastem stock rose ~17.0% to $6.53 from its previous close of $5.58 on June 14.
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 18) Aptose Biosciences Inc (NASDAQ: APTO ) Arrowhead Pharmaceuticals ...
